arrow
G

Giovanni Luca Frassineti

IRCCS Ospedale San Raffaele
H指数:41
被引数:6,314

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab
2024-08-301
OAAI
Circulating tumor DNA (ctDNA) testing in tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the LIquid BIopsy monoclonal Antibodies (LIBImAb) study
2024-06-010
PRE
Multicentre, multi-cohort, single-arm phase II trial of tremelimumab and durvalumab as neoadjuvant or definitive treatment of patients (pts) with microsatellite instabilityhigh (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): The INFINITY study
2024-06-010
PRE
Maintenance therapy with regorafenib (REGO) versus placebo after first-line (1L) platinum and fluoropyrimidinesbased chemotherapy in HER2-negative advanced gastric (GC)/gastroesophageal junction (GEJ) cancer: Results of phase II randomized a-MANTRA study (GOIRC-05-2016)
2024-06-010
PRE
Switch maintenance with ramucirumab plus paclitaxel versus continuation of oxaliplatin-based chemotherapy in advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: Final results and key biomarkers of the ARMANI phase III trial
2024-06-010
PRE
Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab
2023-12-116
OAAI
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV
2023-12-012
OA
Impact of immunological alterations and post-operative biomarkers on long-term outcomes in patients with locally advanced rectal cancer: Results from the STAR-01 study cohort
2023-10-010
OAAI
Capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer (PANDORA trial): Molecular profiling and translational results
2023-10-010
OA
Non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) guideline application in real-world: MultiInstitutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI)
2023-10-010
OA
Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial
2023-10-0117
OAAI
Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study
2023-07-0112
PRE